INTRODUCTION {#s01}
============

Germinal center (GC) response is one of the defining features of adaptive immunity. T and B cells interact in specialized structures called GCs that form within secondary lymphoid organs after encountering pathogens or vaccination. GC B cells undergo class switch recombination, somatic hypermutation, affinity maturation, and differentiation into plasma cells and memory B cells. A distinct CD4^+^ effector T cell subset, T follicular helper cells (Tfh cells), provides critical help to B cells in the GC response ([@bib8]). Recent studies suggest that Tfh cell differentiation and function are essential in the control of chronic virus infections ([@bib13]; [@bib22]; [@bib27]), whereas Tfh cell expansion has been observed in a subset of patients with autoimmune diseases and several mouse models of autoimmunity and was shown to play a causative role in disease pathogenesis in some models ([@bib31]; [@bib46]; [@bib54]). Therefore, elucidating the cellular and molecular mechanisms underlying Tfh cell differentiation and function is of fundamental importance for the design of better vaccines and therapies aimed to boost antibody production in infectious settings or to mute autoantibody production in autoimmune diseases.

MicroRNAs (miRNAs) are endogenously encoded small RNAs that regulate the expression of protein-coding genes by pairing with their target mRNAs and promoting their degradation or translational repression ([@bib2]). Hundreds of miRNAs are expressed in the immune system ([@bib29]). Genetic studies have demonstrated that miRNAs are critical regulators of the GC response ([@bib3]). Thus, T cell--specific ablation of *DiGeorge syndrome critical region gene 8* (*Dgcr8*), a critical subunit of the microprocessor complex that mediates the biogenesis of pre-miRNAs from the primary miRNA transcripts, results in severe defects in Tfh cell differentiation ([@bib4]). Antigen-specific *Dgcr8*-deficient CD4^+^ T cells exhibited impaired proliferation, failed to up-regulate Bcl6 and CXCR5, and were unable to enter B cell follicles during immune responses ([@bib4]). Recent studies of individual miRNA genes that regulate Tfh cell differentiation have been focused on the miR-17∼92 family miRNAs, which control the expression of Bcl6 and CXCR5 in antigen-specific CD4^+^ T cells, as well as their migration into B cell follicles. However, miR-17∼92 family miRNA-deficient antigen-specific CD4^+^ T cells exhibited normal in vivo proliferation, suggesting that other miRNA genes are responsible for controlling cellular proliferation during Tfh cell differentiation ([@bib4]; [@bib27]).

In this study, we performed deep sequencing analysis of miRNAs expressed in Tfh cells and identified a five-miRNA signature that is highly induced upon Tfh cell differentiation. Functional analyses of mutant mice deficient of these Tfh-specific miRNAs revealed that miR-155 promotes the generation and function of Tfh cells. Further mechanistic studies identified a miR-155--Peli1--c-Rel pathway that specifically controls the late stage proliferation of and CD40 ligand (CD40L) expression on Tfh cells.

RESULTS {#s02}
=======

Deep sequencing identifies a miRNA signature of Tfh cells {#s03}
---------------------------------------------------------

We hypothesized that, in addition to the miR-17∼92 family miRNAs, there are other miRNAs that play important roles in regulating the generation and function of Tfh cells. To identify these miRNAs, we performed small RNA deep sequencing analysis of pre-Tfh and Tfh cells sorted from mice immunized with OVA precipitated in alum together with LPS (OVA/alum/LPS; [Fig. 1 A](#fig1){ref-type="fig"} and [Table S1](http://www.jem.org/cgi/content/full/jem.20160204/DC1){#supp1}). Clustering of the top 60 most variable miRNAs revealed that pre-Tfh and Tfh cells exhibited similar miRNA expression profiles, which are distinct from that of naive CD4^+^ T (CD4^+^CD44^−^CXCR5^−^PD-1^−^) cells sorted from the same immunized mice ([Fig. 1 B](#fig1){ref-type="fig"}). Five miRNAs were found highly induced in pre-Tfh and Tfh cells, including miR-22, miR-148a, miR-182, miR-146a, and miR-155. To validate the small RNA deep sequencing results, we prepared naive CD4^+^ T cells, various T helper cell subsets, and regulatory T cells (T reg cells) in independent experiments and examined the expression of these five miRNAs, as well as signature transcription factors for these cell subsets, by quantitative RT-PCR ([Fig. 1, C and D](#fig1){ref-type="fig"}). Indeed, all of these five miRNAs were highly induced upon differentiation into pre-Tfh cells, and their expression levels were further increased in Tfh cells. We termed these five miRNAs the miRNA signature of Tfh cells.

![**Deep sequencing analysis of miRNA expression profiles of Tfh cells.** (A) FACS sorting strategy to purify CXCR5^int^PD1^lo^ pre-Tfh and CXCR5^hi^PD1^hi^ Tfh cells. WT C57BL/6 mice were immunized with OVA/alum/LPS, and cell subsets were sorted from splenocytes on day 7 after immunization. (B) Heat map of miRNA signatures for naive CD4^+^ T (CD44^−^CXCR5^−^PD1^−^), pre-Tfh, and Tfh cells. The color scale represents the log2 value of miRNA read counts in tags per million. The Tfh cell signature miRNAs are marked in red. See details in [Table S1](http://www.jem.org/cgi/content/full/jem.20160204/DC1){#supp2}. (C and D) Quantitative RT-PCR analysis of individual miRNAs (C) and transcription factors (D) in naive CD4^+^ T, pre-Tfh, Tfh, and in vitro generated Th cell subsets and natural T reg (nTreg) cells. AU, arbitrary units. Error bars represent SD. Data are one representative result of two independent experiments and triplicate for each RT-PCR reaction.](JEM_20160204_Fig1){#fig1}

miR-22 and miR-183/96/182 are dispensable for Tfh cell generation and function {#s04}
------------------------------------------------------------------------------

Among the five miRNAs, KO mice were previously generated and reported for miR-22, miR-146a, miR-155, and the miR-183/96/182 miRNA cluster, which encodes for miR-183, miR-96, and miR-182 ([@bib44]; [@bib49]; [@bib5]; [@bib20]; [@bib37]). *miR-148a*--deficient mice are currently not available. Recent studies of *miR-146a*--deficient mice showed that miR-146a played a negative role in the generation and accumulation of Tfh cells and GC B cells and that miR-146a repressed several Tfh cell--expressed genes ([@bib24]; [@bib42]). To examine the functions of other Tfh cell signature miRNAs, we immunized mice deficient of *miR-22* or the *miR-183*/*96*/*182* cluster. It was previously reported that miR-182 is induced by IL-2 and plays a potent role in promoting clonal expansion of activated helper T cells ([@bib48]), suggesting that it may have an important function in Tfh cell generation. Surprisingly, the generation of Tfh cells was normal in both *miR-22*-- and *miR-183*/*96*/*182*--deficient mice ([Fig. 2, A and D](#fig2){ref-type="fig"}). In addition, GC B cell formation and antigen-specific antibody production were not affected by the loss of miR-22 or miR-183/96/182 ([Fig. 2, B, C, E, and F](#fig2){ref-type="fig"}). Therefore, miR-22 and the miR-183/96/182 cluster are dispensable for Tfh cell generation and function.

![**miR-22 and miR-183/96/182 are dispensable for Tfh cell generation and function.** (A, B, D, and E) WT, *miR-22^−/−^*, and *miR-183*/*96*/*182^−/−^* mice were immunized with OVA/alum/LPS, and CXCR5^hi^Bcl6^+^ Tfh cells (A and D) and FAS^hi^GL7^hi^ GC B cells (B and E) were analyzed on day 7 after immunization by flow cytometry. (Left) Representative FACS plots. (Right) Summary of percentages of Tfh and GC B cells. (C and F) In independent experiments, NP-OVA/alum--immunized mice were bled at the indicated time points, and the amounts of NP-specific IgG1 were determined by ELISA. Each symbol represents an individual mouse. Horizontal lines indicate the mean. *n* = 3--7.](JEM_20160204_Fig2){#fig2}

miR-155 deficiency in T cells leads to impaired generation of Tfh cells {#s05}
-----------------------------------------------------------------------

Previous studies showed that miR-155 plays a critical role in controlling GC responses and Tfh cell generation, but the underlying cellular and molecular mechanisms remain poorly understood ([@bib44]; [@bib49]; [@bib52]; [@bib24]). To investigate the T cell--intrinsic role of miR-155 in Tfh cell generation, we generated mixed BM chimeras with T cell--specific loss of miR-155, which were created by reconstituting sublethally irradiated *Rag1^−/−^* mice with 80% of *Tcrb^−/−^Tcrd^−/−^* (TCD) plus 20% of WT or *miR-155^−/−^* (KO) BM cells ([Fig. 3 A](#fig3){ref-type="fig"}). The *Tcrb^−/−^Tcrd^−/−^* mutation prevents the generation of T cells; therefore, T cells in the animals receiving *miR-155^−/−^* BM will be *miR-155* deficient (KO + TCD), whereas the recipients of WT BM will have WT T cells (WT + TCD). The 80:20 ratio favors reconstitution of all the other hematopoietic lineages from WT precursors. Both groups of chimeras have similar percentages and numbers of B and T cells (unpublished data). We immunized these mice with OVA/alum/LPS or 4-hydroxy-3-nitrophenyl (NP) linked to OVA precipitated in alum (NP-OVA/alum) to study the effect of T cell--specific *miR-155* deficiency on GC reaction and antibody responses ([Fig. 3 A](#fig3){ref-type="fig"}). The KO + TCD chimeras showed severe defects in the generation of GC B and Tfh cells and produced decreased amounts of total and high-affinity NP-specific IgG1 antibody ([Fig. 3, B--D](#fig3){ref-type="fig"}). The KO + TCD chimeras also had a defective secondary antibody response after reimmunization ([Fig. 3 E](#fig3){ref-type="fig"}), suggesting that miR-155 expression in T cells is required not only for the initial generation and function of Tfh cells, but also for the establishment of long-lived protective CD4^+^ T cell--dependent B cell responses. These mice produced NP-specific IgM antibody in amounts comparable with that produced by WT + TCD chimeras ([Fig. 3 D](#fig3){ref-type="fig"}), suggesting that general B cell activation and plasma cell differentiation were not affected by the absence of miR-155 expression in T cells. These results demonstrate a T cell--intrinsic requirement of miR-155 for the generation of Tfh cells and GC B cells, as well as the production of high-affinity and class-switched antibodies.

![**T cell--intrinsic requirement of miR-155 for generating GC B and Tfh cells.** (A--D) Generation and immunization of mixed BM chimera mice with T cell--specific loss of miR-155. Sublethally irradiated *Rag1^−/−^* mice were reconstituted with BM cells from *miR-155^−/−^* and *Tcrb^−/−^Tcrd^−/−^* (TCD) or WT and TCD mice at a 1:4 ratio and subsequently immunized with OVA/alum/LPS (B and C) or NP-OVA/alum (D). (B, left) Flow cytometry analysis of Tfh cells. Numbers adjacent to the outlined areas indicate percentages of CXCR5^hi^PD1^hi^ (top) and CXCR5^hi^Bcl-6^+^ (bottom) Tfh cells among total CD4^+^ T cells. (Right) Summary of the percentage and cell number of CXCR5^hi^PD1^hi^ and CXCR5^hi^Bcl-6^+^ Tfh cells. (C, left) Flow cytometry analysis of GC B cells. Numbers adjacent to the outlined areas indicate the percentage of GC B cells (Fas^hi^GL7^hi^) among total B cells (B220^+^). (Right) Summary of the percentage of GC B cells. (D) ELISA analysis of NP-specific IgM (top), total NP-specific IgG1 (middle), and high-affinity anti-NP IgG1 (bottom) antibodies in the sera from NP-OVA/alum--immunized mice. (E) Mixed BM chimera mice in [Fig. 3 A](#fig3){ref-type="fig"} were reimmunized with NP-OVA 3 mo after primary immunization. Total anti-NP IgG1 in the sera was determined by ELISA. Each dot represents an individual mouse. Horizontal lines indicate the mean. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (Student's *t* test). Data were combined from two independent experiments (B and C). *n* = 6--8.](JEM_20160204_Fig3){#fig3}

miR-155 is specifically required for the late stage of proliferation during Tfh cell differentiation {#s06}
----------------------------------------------------------------------------------------------------

We introduced the transgene encoding the OVA-specific OT-II TCR into *miR-155^−/−^* mice to study the effect of miR-155 on antigen-specific CD4^+^ T cells during Tfh cell differentiation ([@bib1]). We labeled naive CD45.2^+^ WT or *miR-155^−/−^* OT-II CD4^+^ T cells with the cytosolic dye CFSE and adoptively transferred them into CD45.1^+^ WT recipients, immunized the recipients with OVA/alum, and analyzed the transferred OT-II CD4^+^ T cells in draining lymph nodes at various time points. The percentage of adoptively transferred *miR-155^−/−^* OT-II cells among total CD4^+^ T cells was comparable with that of their WT counterparts on days 2.5 and 3.5 after immunization but was drastically decreased by day 6.5, when both the percentage and absolute number of *miR-155^−/−^* OT-II and CXCR5^hi^Bcl6^+^ Tfh cells were threefold less than that of WT OT-II cells ([Fig. 4, A and B](#fig4){ref-type="fig"}). Among *miR-155^−/−^* OT-II cells, the frequency of CXCR5^hi^Bcl6^+^ Tfh cells was comparable with that among WT OT-II cells ([Fig. 4 C](#fig4){ref-type="fig"}). These data suggest that much fewer Tfh cells were generated from *miR-155^−/−^* OT-II cells than from WT OT-II cells because of the lower numbers of *miR-155^−/−^* OT-II cells by day 6.5 ([Fig. 4 B](#fig4){ref-type="fig"}). The expression of Tfh cell markers, such as CXCR5, PD-1, and Bcl6, and activation markers, such as CD44 and inducible T cell co-stimulator (ICOS), was marginally affected by *miR-155* deficiency (unpublished data). The reduction in *miR-155^−/−^* OT-II cells on day 6.5 could be caused by a decrease of cell proliferation, an increase of cell death, or both. Examination of CFSE dilution showed that *miR-155^−/−^* OT-II cells proliferated less than WT OT-II cells between days 3.5 and 6.5 ([Fig. 4, D and E](#fig4){ref-type="fig"}), whereas cell death was not significantly affected by *miR-155* deficiency ([Fig. 4 E](#fig4){ref-type="fig"}, bottom). These results prompted us to examine the de novo expansion of antigen-specific CD4^+^ T cells at different stages of Tfh cell differentiation. In the same experimental setting as in [Fig. 4 (A--D)](#fig4){ref-type="fig"}, BrdU was injected into immunized recipient mice 1 d before analysis to label cells undergoing proliferation, and OT-II cells were analyzed on day 3 or 4.5 for BrdU incorporation. Consistent with the CFSE dilution results ([Fig. 4 D](#fig4){ref-type="fig"}), *miR-155^−/−^* OT-II cells exhibited impaired proliferation between days 3.5 and 4.5 but not between days 2 and 3 after immunization ([Fig. 4 F](#fig4){ref-type="fig"}). We also examined the location of *miR-155^−/−^* OT-II CD4^+^ cells in draining lymph nodes during immune responses. Consistent with their reduced frequency, the density of *miR-155^−/−^* OT-II CD4^+^ cells (identified by CD45.2 staining) in draining lymph nodes was much lower than that of WT OT-II CD4^+^ cells ([Fig. 4, G and H](#fig4){ref-type="fig"}). The reduction in *miR-155^−/−^* OT-II CD4^+^ cell density was found in both B and T cell zones, suggesting that the migration of CD4^+^ cells from the T cell zone into B cell follicles is not affected by *miR-155* deficiency ([Fig. 4, G and H](#fig4){ref-type="fig"}). Together, these results reveal a critical role of miR-155 in controlling the proliferation of antigen-specific CD4^+^ T cells, specifically at the late stage of Tfh cell differentiation, but not their survival or migration.

![**miR-155 controls the optimal expansion of antigen-specific CD4^+^ T cells.** (A--H) Naive CD4^+^CD45.2^+^ T cells from WT or miR-155^−/−^ OT-II (KO) mice were adoptively transferred into WT CD45.1^+^ mice. Recipient mice were immunized with OVA/alum subcutaneously into the flank 1 d after cell transfer. Cells in the draining lymph nodes were analyzed by flow cytometry at the indicated time points. (A) Flow cytometry analysis of CD45.2^+^ OT-II cells among total CD4^+^ T cells. (B) Absolute number of transferred OT-II CD4^+^ T and CXCR5^hi^Bcl-6^+^ Tfh cells in draining lymph nodes at 6.5 d after immunization. (C) Flow cytometry analysis of CXCR5^hi^Bcl6^+^ Tfh cells among CD4^+^CD45.2^+^ OT-II cells. (D) Flow cytometry analysis of cell proliferation of CD4^+^CD45.2^+^ OT-II cells. The proliferation index was calculated by using FlowJo analysis. (E) Percentage of CD45.2^+^ OT-II cells with five or more cell divisions (bottom) and active caspase 3^+^ (apoptotic) cells among CD4^+^CD45.2^+^ OT-II cells on day 6.5 after immunization (top). Representative figures were adapted from the experiment in D to indicate that the cells underwent five or more cell divisions. Error bars represent SD. (F) BrdU was injected into mice i.p. on day 2 or day 3.5 after immunization and euthanized for analysis 24 h later (day 3 or day 4.5, respectively). CD4^+^CD45.2^+^ OT-II cells were analyzed by flow cytometry for BrdU incorporation (BrdU^+^). (G) Immunohistochemistry of WT or miR-155^−/−^ OT-II cells in draining lymph nodes. Cryosections of the draining lymph nodes from the immunized recipient mice were stained with CD45.2 (white, adoptively transferred OT-II cells) and IgD (red, naive B cells) and analyzed by fluorescence microscopy. Bar, 70 µm. (H) Cell density of CD45.2^+^ OT-II cells in the whole area and B cell zone. Each dot represents an individual mouse. Horizontal lines indicate the mean. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (Student's *t* test). ns, not significant. *n* = 3--14.](JEM_20160204_Fig4){#fig4}

miR-155 controls c-Rel and CD40L expression by targeting Peli1 {#s07}
--------------------------------------------------------------

Previous studies showed that the strength of TCR binding plays an important role in the Tfh cell differentiation program, suggesting the functional importance of initial T cell activation in the generation of Tfh cells ([@bib14]; [@bib50]). To elucidate the molecular mechanisms through which miR-155 controls the generation of Tfh cells, we first investigated whether miR-155 deficiency affects T cell activation by determining IL-2 production and expression of activation markers. TCR- and CD28-mediated IL-2 production by *miR-155^−/−^* CD4^+^ T cells was largely normal (unpublished data). The expression of activation markers such as CD25, CD44, CD69, and ICOS was comparable between *miR-155^−/−^* and WT CD4^+^ T cells (unpublished data). Surface expression of CD71 (transferrin receptor) on *miR-155^−/−^* CD4^+^ T cells showed a slight reduction, which did not reach statistical significance (unpublished data). In contrast, surface expression of CD40L, which is essential for T cell--B cell interaction during GC response ([@bib8]), on *miR-155^−/−^* CD4^+^ T cells was reduced to 64.5% (16 h) and 50% (40 h) of WT levels ([Fig. 5 A](#fig5){ref-type="fig"}). Therefore, miR-155 specifically regulates CD40L expression during T cell activation.

![**miR-155 controls c-Rel and CD40L expression by targeting Peli1 in T cells.** (A--J) Naive CD4^+^ T cells from *miR-155^−/−^* (KO) and WT mice were stimulated with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 antibodies for the indicated amounts of time. (A) Surface expression of CD40L was analyzed by flow cytometry. The bar graph summarizes mean fluorescence intensity (MFI) of CD40L. *n* = 4--7 per group. (B and C) Immunoblot analysis of p65, RelB, and c-Rel in the nuclear extracts of naive CD4^+^ T cells from *miR-155^−/−^* (KO) and WT mice stimulated with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 antibodies for the indicated amounts of time. Two independent immunoblot experiments were normalized by β-actin and summarized in C. (D) Schematic representation of the Peli1 3′UTR and the miR-155--binding region. The figure was adapted from CLIP base ([@bib33]). Note that Ago2 binding to the miR-155 site is much reduced in in vitro activated *miR-155^−/−^* CD4^+^ T cells. (E) Reporter assay of the *Peli1* 3′UTR fragment containing the WT or mutated miR-155--binding site. (F and G) Immunoblot analysis of Peli1, c-Rel, and β-actin expression in naive CD4^+^ T cells stimulated with 5 µg/ml anti-CD3 and 2 µg/ml anti-CD28 antibodies for the indicated amounts of time. Four independent immunoblot experiments were normalized by β-actin and summarized in G. (H) Immunoblot analysis of Peli1, c-Rel, and β-actin expression in WT and *miR-155^−/−^* (KO) CD4^+^ T cells transduced with control or Peli1 shRNA (P1 sh)--encoding RVs. (I) Immunoblot analysis of c-Rel and β-actin expression in WT and *miR-155^−/−^* (KO) CD4^+^ T cells transduced with control or c-Rel--encoding RVs. (H and I, left) Representative immunoblots. (Right) Bar graphs showing quantification results. (J) Flow cytometry analysis of CD40L expression on RV-transduced CD4^+^ T cells 1 d after retroviral transduction. The bar graph summarizes mean fluorescence intensity of CD40L. *n* = 5 per group. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (Student's *t* test). Data represent two (B, C, I, and J), three (H), and four (A, E, F, and G) independent experiments. Error bars represent SD.](JEM_20160204_Fig5){#fig5}

It was previously reported that NF-κB binds to the distal end of the *CD40L* promoter and up-regulates *CD40L* transcription ([@bib47]; [@bib45]; [@bib41]). miR-155 may control CD40L expression by regulating the activity of NF-κB transcription factors. To test this hypothesis, we examined nuclear accumulation of NF-κB family members during T cell activation. The nuclear protein levels of RelA (p65) and RelB were normal in activated *miR-155^−/−^* CD4^+^ T cells, whereas nuclear accumulation of c-Rel was much lower in these cells than in WT cells ([Fig. 5, B and C](#fig5){ref-type="fig"}). As c-Rel also regulates T cell proliferation in a dosage-dependent manner ([@bib28]), it is very likely that miR-155 controls both CD40L expression and the proliferation of antigen-specific CD4^+^ T cells by regulating nuclear accumulation of c-Rel.

To gain insights into the molecular pathway through which miR-155 controls c-Rel and CD40L expression, we analyzed the list of miR-155 target genes experimentally identified by using differential high-throughput sequencing of RNA isolated by cross-linking and immunoprecipitation (CLIP) of Argonaute 2 (Ago2) in activated CD4^+^ T cells ([@bib33]). We looked for potential miR-155 target genes implicated in the regulation of NF-κB activation in T cells. Peli1 was selected because it acts as an E3 ubiquitin ligase of c-Rel and negatively regulates nuclear accumulation of c-Rel by promoting its degradation ([@bib6]). There is one evolutionarily conserved miR-155 binding site in the 3′ untranslated region (UTR) of the *Peli1* mRNA. Ago2 binding to this site was significantly reduced in *miR-155^−/−^* CD4^+^ T cells ([Fig. 5 D](#fig5){ref-type="fig"}), suggesting that it is a bona fide miR-155 target site. To demonstrate direct regulation of Peli1 by miR-155, we performed a dual-luciferase reporter assay. A Peli1 3′UTR fragment containing the miR-155 binding site was cloned into the expression vector psiCHECK2, which encodes the Renilla luciferase controlled by the cloned 3′UTR. The resulting construct was cotransfected in HEK293 cells with an expression vector encoding miR-155, and regulation of protein expression by miR-155 was measured by luciferase activity. As shown in [Fig. 5 E](#fig5){ref-type="fig"}, miR-155 significantly reduced protein expression through the Peli1 3′UTR. When the miR-155 binding site was mutated, the reduction in protein expression was abolished, indicating that miR-155 suppresses the expression of Peli1 through its cognate binding site in the Peli1 3′UTR.

Consistent with miR-155 suppression of Peli1 expression and the promotion of c-Rel degradation by Peli1, in vitro activated *miR-155^−/−^* CD4^+^ T cells expressed more Peli1 and less c-Rel proteins than their WT counterparts ([Fig. 5, F and G](#fig5){ref-type="fig"}). We also examined the protein levels of a small number of other miR-155 target genes identified by differential high-throughput sequencing of CLIP ([@bib33]) and implicated in various aspects of T cell biology. The protein levels of Fbxo11 and SHIP1 were not affected by miR-155 deficiency (unpublished data). Therefore, Peli1 represents an authentic target gene of miR-155 in this cellular context.

To further test the hypothesis that miR-155 regulates c-Rel and CD40L expression by suppressing the expression of Peli1, we used retrovirus (RV)-encoded shRNA to knock down the expression of Peli1 and RV-encoded c-Rel to overexpress c-Rel in *miR-155^−/−^* CD4^+^ T cells. RV-Peli1 shRNA restored Peli1 and c-Rel expression close to WT levels ([Fig. 5 H](#fig5){ref-type="fig"}), whereas RV--c-Rel increased c-Rel expression to a level that was slightly higher than the WT level ([Fig. 5 I](#fig5){ref-type="fig"}). Both Peli1 knockdown and c-Rel reexpression substantially restored CD40L expression in *miR-155^−/−^* CD4^+^ T cells ([Fig. 5 J](#fig5){ref-type="fig"}). Collectively, these results demonstrate that miR-155 controls c-Rel and CD40L expression by suppressing the expression of its target gene, Peli1.

Restoration of Tfh cell generation and function by reducing Peli1 in *miR-155^−/−^* T cells {#s08}
-------------------------------------------------------------------------------------------

c-Rel and CD40L are critical regulators of the GC response ([@bib8]; [@bib17]). We next asked whether correcting Peli1 expression in *miR-155^−/−^* CD4^+^ T cells would rescue the GC response defects caused by miR-155 deficiency in T cells. *miR-155^−/−^* OT-II CD4^+^ T cells were transduced with RV-Peli1 shRNA and transferred into TCD recipient mice, which were subsequently immunized with OVA/alum. Although WT OT-II CD4^+^ T cells support the GC response in TCD mice, *miR-155^−/−^* OT-II CD4^+^ T cells exhibited a severe reduction in cell numbers and an inability to provide help to B cells ([Fig. 6 A](#fig6){ref-type="fig"}). Strikingly, knocking down Peli1 expression rescued the B cell help ability of *miR-155^−/−^* OT-II CD4^+^ T cells by ∼60--70%, as indicated by increased formation of GC B and Tfh cells, as well as by elevated *miR-155^−/−^* OT-II CD4^+^ T and Tfh cell numbers ([Fig. 6, A--C](#fig6){ref-type="fig"}). Accordingly, the production of total and high-affinity NP-specific antibodies was largely restored ([Fig. 6 D](#fig6){ref-type="fig"}).

![**Peli1 knockdown in *miR-155^−/−^* T cells substantially restores the GC response.** (A--D) WT and *miR-155^−/−^* (KO) OT-II CD4^+^ T cells transduced with control or Peli1 shRNA (P1 sh)--encoding RVs were adoptively transferred into TCD mice and subsequently immunized with OVA/alum. Splenocytes were prepared from recipient mice on day 10 after immunization. (A) Flow cytometry analysis of GC B cells among total B cells. (B and C) Percentage (B) and total cell numbers (C) of CXCR5^hi^Bcl6^+^ Tfh cells among CD4^+^ T cells (left) and OT-II CD4^+^ T cells among total splenocytes (right) are shown. (D) ELISA analysis of NP-specific IgG1 antibodies in the sera after NP-OVA/alum immunization. Serum titers of total (left) and high-affinity (right) NP-specific IgG1 antibodies are shown. Each symbol represents an individual mouse. Horizontal lines indicate the mean. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (Student's *t* test). Data were combined from two independent experiments. ns, not significant. *n* = 5--9.](JEM_20160204_Fig6){#fig6}

We next used a genetic approach to modulate Peli1 expression in *miR-155^−/−^* mice. As shown in [Fig. 7 (A and B)](#fig7){ref-type="fig"}, *miR-155^−/−^;Peli1^+/−^* mice exhibited largely restored generation of Tfh and GC B cells on day 8 after OVA/alum/LPS immunization. To determine whether the effect of genetic rescue on Tfh generation is T cell intrinsic, we generated mixed BM chimera mice with mixed BM cells (TCD BM + WT, *miR-155^−/−^*, or *miR-155;Peli1^+/−^* BM) in a *Rag1^−/−^* background and immunized the chimera mice with NP-OVA/alum/LPS ([Fig. 7 C](#fig7){ref-type="fig"}). Heterozygous deletion of *Peli1* in *miR-155^−/−^* T cells substantially rescued the impaired Tfh cell generation caused by miR-155 deficiency ([Fig. 7 D](#fig7){ref-type="fig"}). Peli1 heterozygosity also restored Tfh function, as indicated by close to WT levels of GC B cell numbers ([Fig. 7 E](#fig7){ref-type="fig"}) and class-switched and affinity-matured antigen-specific antibodies ([Fig. 7 F](#fig7){ref-type="fig"}). These results demonstrate that Peli1 is a major mediator of miR-155 function in CD4^+^ T cells to control Tfh cell generation, GC response, and antibody production.

![**Heterozygous *Peli1* deletion restores GC response in *miR-155^−/−^* mice.** (A and B) Splenocytes were prepared from WT, *miR-155^−/−^*, *Peli1^+/−^*, and *miR-155^−/−^;Peli1^+/−^* mice on day 8 after immunization with OVA/alum/LPS. CXCR5^hi^Bcl-6^+^ Tfh cells (top) among total CD4^+^ T cells and FAS^+^GL7^+^ GC B cells (bottom) were analyzed by flow cytometry (A) and represented as dot plots (B). (C) Chimera mice were generated by reconstitution of irradiated *Rag1^−/−^* mice with BM cells from WT and TCD, KO and TCD, or KO;*Peli^+/−^* and TCD at a 1:4 ratio. The chimera mice were subsequently immunized with NP-OVA/alum/LPS. (D and E) CXCR5^hi^Bcl-6^+^ Tfh cells (D) and FAS^hi^GL7^hi^ GC B cells (E) were analyzed from spleen after 8 d of immunization by flow cytometry, and combined results are exhibited as dot plots. (F) Amounts of NP-specific total and affinity-matured antibodies were determined by ELISA on day 10 after immunization. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (Student's *t* test). ns, not significant. *n* = 4--10.](JEM_20160204_Fig7){#fig7}

Reexpression of c-Rel restores Tfh cell generation and function of *miR-155*--deficient T cells {#s09}
-----------------------------------------------------------------------------------------------

It was previously reported that germline deletion of the *Rel* gene (encoding c-Rel) caused severely compromised B and T cell proliferation and antibody production and that conditional deletion of *c-Rel* in activated B cells led to impaired production of high-affinity antibodies because of the collapse of established GCs ([@bib28]; [@bib23]). However, the function of c-Rel in the generation and function of Tfh cells remains unclear. As we found that the c-Rel protein levels in CD4^+^ T cells is controlled by miR-155 via Peli1 and that c-Rel modulates CD4^+^ T cell expression of CD40L, which is critical for the function of Tfh cells during the GC response, we speculated that the c-Rel protein level in CD4^+^ T cells is critical for Tfh cell generation and function. To explore the functional importance of c-Rel in T cells, we immunized WT, *Rel^+/−^*, and *Rel^−/−^* mice with NP-OVA/alum/LPS. As shown in [Fig. 8 (A and B)](#fig8){ref-type="fig"}, *Rel^−/−^* mice exhibited drastically reduced numbers of Tfh and GC B cells, whereas *Rel^+/−^* mice had similar but milder phenotypes. These results suggest that c-Rel controls Tfh cell generation and function in a dose-dependent manner.

![**Reexpression of c-Rel restores Tfh cell generation and function of *miR-155^−/−^* T cells.** (A and B) WT, *Rel^+/−^*, and *Rel^−/−^* mice were immunized with OVA/alum/LPS i.p., and the spleen was analyzed for CXCR5^hi^Bcl6^+^ Tfh (A) and FAS^+^GL7^+^ GC B (B) cells on day 8 after immunization by flow cytometry. (C--F) c-Rel--encoding or control RVs were transduced into WT and *miR-155^−/−^* (KO) OT-II CD4^+^ T cells, adoptively transferred into TCD mice, and immunized subsequently with NP-OVA/alum/LPS. Spleens were analyzed for GC B (C) and Tfh (D) cells by flow cytometry, and amounts of antigen-specific antibodies (F) were determined by ELISA on day 10 after immunization. \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001 (Student's *t* test). *n* = 3--5.](JEM_20160204_Fig8){#fig8}

We hypothesized that impaired Tfh cell generation and function in *miR-155^−/−^* mice is mainly caused by reduced c-Rel protein levels in CD4^+^ T cells. To test this hypothesis, we attempted to rescue the Tfh cell defects by restoring c-Rel protein levels in *miR-155^−/−^* CD4^+^ T cells. We transduced *miR-155^−/−^* OT-II CD4^+^ T cells with a c-Rel--expressing RV, adoptively transferred them into TCD mice, and immunized the recipient mice with NP-OVA/alum. Strikingly, retroviral expression of c-Rel completely restored the generation and function of Tfh cells from *miR-155^−/−^* OT-II cells ([Fig. 8, C--E](#fig8){ref-type="fig"}), as well as the production of class-switched and affinity-matured antigen-specific antibodies ([Fig. 8 F](#fig8){ref-type="fig"}). Collectively, these results demonstrated that the miR-155--Peli1--c-Rel pathway plays a critical role in controlling the generation and function of Tfh cells.

The miR-155--Peli1--c-Rel pathway is dispensable for the generation of cytotoxic CD8, Th1, and Th17 cells {#s10}
---------------------------------------------------------------------------------------------------------

Previous studies showed that miR-155 plays critical roles in other immune cells, such as cytotoxic CD8^+^ T cells, Th1 cells, and Th17 cells ([@bib39]; [@bib10]; [@bib18]; [@bib12]). To examine whether Peli1 functions as a key miR-155 target gene in these cell contexts, WT, *miR-155^−/−^*, and *miR155^−/−^;Peli1^+/−^* mice were challenged with lymphocytic choriomeningitis virus (LCMV) Armstrong, whose clearance requires intact cytotoxic CD8^+^ T cell function. As shown in [Fig. 9 (A and B)](#fig9){ref-type="fig"}, *miR-155^−/−^* mice showed compromised generation of IFN-γ--producing effector CD8^+^ T cells, but this defect was not rescued in *miR-155^−/−^;Peli1^+/−^* mice. These mice were also examined in the experimental autoimmune encephalomyelitis (EAE) model to study whether the miR-155--Peli1 axis functions in the generation of Th1 and Th17 cells. Consistent with previous studies, *miR-155^−/−^* mice were defective in the generation of both Th1 and Th17 cells ([@bib39]; [@bib12]). Heterozygous deletion of *Peli1* cannot rescue these defects ([Fig. 9, C and D](#fig9){ref-type="fig"}). Collectively, these results showed that miR-155 regulation of Peli1 is dispensable for the generation of cytotoxic CD8^+^ T, Th1, and Th17 cells, thereby highlighting the functional specificity of the miR-155--Peli1 pathway in regulating the generation of Tfh cells.

![**miR-155 regulation of Peli1 is dispensable for the generation of cytotoxic CD8^+^ T, Th1, and Th17 cells.** (A and B) Flow cytometry analysis of IFN-γ--producing effector CD8^+^ T cells from the spleen of WT, *miR-155^−/−^*, and *miR155^−/−^;Peli1^+/−^* mice at day 8 after LCMV Armstrong infection (gated on CD8^+^ T cells). (C and D) Flow cytometry analysis of Th1 and Th17 cells from draining lymph nodes of WT, *miR-155^−/−^*, and *miR155^−/−^;Peli1^+/−^* mice at day 14 after the induction of EAE (gated on CD4^+^ T cells). \*, P \< 0.05; \*\*\*, P \< 0.001 (Student's *t* test). ns, not significant. *n* = 5--7.](JEM_20160204_Fig9){#fig9}

DISCUSSION {#s11}
==========

A previous study has shown that miRNAs control several facets of Tfh cell differentiation, including cellular proliferation, up-regulation of CXCR5 and Bcl6, and migration of CD4^+^ T cells into B cell follicles ([@bib4]). Recent studies from us and other investigators found that the miR-17∼92 family miRNAs regulate the expression of CXCR5 and Bcl6, as well as CD4^+^ T cell migration into B cell follicles, but not proliferation of antigen-specific CD4^+^ T cells ([@bib4]; [@bib27]), suggesting that additional miRNAs regulate the generation and function of Tfh cells. In the present study, we performed the first deep sequencing analysis of miRNA expression profiles of pre-Tfh and Tfh cells and identified five miRNAs that are highly induced upon Tfh cell differentiation. They include miR-22, miR-148a, miR-182, miR-146a, and miR-155.

By analyzing Tfh cell generation, GC B cell formation, and production of class-switched antibodies in mutant mice deficient of these individual miRNA genes, we found that miR-22 and miR-183/96/182 are dispensable, whereas miR-155 is essential for Tfh cell generation and function. This result is surprising because miR-182 was previously reported to play a potent role in promoting clonal expansion of activated Th cells ([@bib48]), an integral component of the Tfh cell differentiation program. As miRNAs encoded by this cluster are highly induced in several Th cell subsets ([Fig. 1 C](#fig1){ref-type="fig"}; [@bib29]), it is possible that they play critical roles in some of these cellular contexts. Indeed, results from our collaborators showed that miR-183/96/182 regulates pathogenic cytokine expression during Th17 cell development ([@bib26]). Studies from other investigators showed that miR-146a plays a negative role in Tfh cell generation and accumulation, likely through suppressing several Tfh cell--expressing genes ([@bib24]; [@bib42]). The potential role of miR-148a, another Tfh-specific miRNA, in Tfh cell generation and function remains to be explored. This awaits the creation and analysis of mutant mice deficient of this gene.

This study identified the miR-155--Peli1--c-Rel axis as a novel pathway that plays critical roles in CD4^+^ T cells to control the generation and function of Tfh cells by regulating their proliferation specifically at the late stage of Tfh cell differentiation and CD40L expression on these cells. The nexus point of this pathway is the control of c-Rel protein levels by miR-155 and Peli1. Unlike other NF-κB family members that are broadly expressed, high levels of c-Rel are found primarily in B and T cells ([@bib17]). c-Rel is not essential for normal hematopoiesis and lymphopoiesis. Instead, it is required for several functions in mature T and B cells. *c-Rel*--deficient T and B cells are severely impaired in cellular proliferation in response to various stimuli ([@bib28]), whereas *c-Rel^−/−^* mice exhibit defective GC response and production of class-switched antibodies ([@bib7]). The functions of c-Rel are very sensitive to its gene dosage. *c-Rel* heterozygosity leads to defects at the cellular and animal levels that are similar to, but milder than, that caused by a complete loss of c-Rel ([@bib28]). The critical functions of c-Rel in lymphocytes and its haploinsufficiency make it an ideal target for miR-155 and Peli1. miR-155, Peli1, and c-Rel are all strongly induced upon T cell activation by the engagement of TCR and co-stimulation molecules ([@bib21]; [@bib49]; [@bib6]). The results presented in this study show that miR-155 sets the Peli1 expression level in a proper range to allow the optimal induction of c-Rel, whose expression must be tightly controlled. Inadequate expression of c-Rel results in impaired B and T cell activation, as well as diminished GC response and antibody production ([@bib28]; [@bib7]), whereas exaggerated c-Rel expression is associated with autoimmune diseases and lymphomas ([@bib17]). In the present study, we showed that c-Rel is a dose-dependent regulator of Tfh cell generation and function. c-Rel controls two critical aspects of the Tfh cell program: proliferation of antigen-specific CD4^+^ T cells and expression of CD40L on these cells. In the absence of miR-155, CD4^+^ T cells express increased amounts of Peli1, which leads to reduced nuclear accumulation of c-Rel and, therefore, impaired proliferation of antigen-specific CD4^+^ T cells at the late stage of Tfh cell differentiation and compromised expression of CD40L on these cells.

The CD40L--CD40 interaction is essential for CD4^+^ T cells to provide critical help to B cells during the GC response ([@bib8]). Although CD40 is constitutively expressed on B cells and other antigen-presenting cells, CD40L is transiently expressed on CD4^+^ T cells upon activation ([@bib9]). Engagement of CD40 leads to B cell clonal expansion, GC formation, isotype switching, affinity maturation, and generation of long-lived plasma cells ([@bib43]). CD40L expression is a limiting factor in the GC response ([@bib40]). Both the magnitude and duration of CD40L expression are subjected to tight regulation ([@bib9]). *CD40L*-deficient mice exhibit impaired T cell--dependent immune response and GC formation ([@bib19]; [@bib51]). CD40L deficiency in humans results in immunodeficiency associated with a severe defect in humoral immune response and a Tfh cell defect. In the absence of CD40L, T cells differentiate poorly into Tfh cells, and B cell--T cell interactions in the GC are impaired ([@bib11]). Conversely, in human systemic lupus erythematosus (SLE) patient and mouse lupus models, CD40L expression on the T cell surface is much prolonged after activation. In addition, high levels of the soluble form of CD40L are found in SLE patient sera. Both the surface and soluble forms of CD40L can activate autoimmune B cells and initiate autoantibody production in SLE ([@bib9]). Our study found that miR-155 specifically controls CD40L expression on CD4^+^ T cells. In the absence of miR-155, activated CD4^+^ T cells express ∼50--65% of WT levels of CD40L. A previous study showed that CD40Ltg^+^ mice exhibited a 1.1--2-fold increase in CD40L expression on activated T cells, and this led to a twofold increase in the production of antigen-specific high-affinity IgG1 antibody ([@bib40]). Conversely, mutant mice with T cell--specific transgenic expression of a dominant-negative TFE3 protein exhibited reduced CD40L expression on activated CD4^+^ T cells, which resulted in impaired GC formation and a drastic decrease in the production of class-switched antibodies ([@bib25]). Considering the high sensitivity of GC response to CD40L expression levels on CD4^+^ T cells, it is likely that the reduction in CD40L expression on *miR-155^−/−^* CD4^+^ T cells contributes to impaired GC response in *miR-155^−/−^* mice.

Our results demonstrate that Peli1 is a key functional target gene of miR-155 in CD4^+^ T cells to regulate Tfh cell generation and function. A previous study has shown that deletion of Peli1 causes hyperactivation of T cells, and *Peli1^−/−^* mice spontaneously develop autoimmune diseases characterized by multiorgan inflammation and autoantibody production ([@bib6]). Peli1 exerts its functions in T cells mainly through promoting the degradation of c-Rel protein and thereby preventing exaggerated accumulation of c-Rel in the nucleus. *miR-155^−/−^* CD4^+^ T cells express increased amounts of Peli1 protein, and correcting Peli1 expression to WT levels by shRNA knockdown substantially rescued GC B cell formation and antibody responses. Furthermore, genetic ablation of one copy of the *Peli1* gene in *miR-155^−/−^* mice substantially restored the generation and function of Tfh cells. These data demonstrate that miR-155 regulation of Peli1 plays a major role in mediating miR-155 control of Tfh cell generation and function.

miR-155 is highly induced upon the activation of T and B cells and plays critical roles in the immune system ([@bib53]). Importantly, miR-155 does not control the general lymphocyte activation and proliferation program. It affects immune responses in a cell type-- and context-specific manner, likely through regulating different downstream target genes and pathways in different cell subsets and biological processes ([@bib36]). Thus, miR-155 promotes the differentiation and accumulation of Th17 cells in EAE through regulating Jarid2 and Socs1 ([@bib39]; [@bib12]; [@bib36]), inhibits Th2 cell differentiation through c-Maf ([@bib44]; [@bib49]), controls the competitive fitness of T reg cells through Socs1 ([@bib35], [@bib36]), and regulates B cell differentiation into plasma cells through PU.1 ([@bib52]; [@bib34]). In this study, we found that miR-155 is highly expressed in pre-Tfh and Tfh cells and plays an essential role in the generation and function of Tfh cells. Mechanistically, it controls cellular proliferation at a late stage of Tfh cell differentiation, as well as CD40L expression, through a novel miR-155--Peli1--c-Rel pathway. Importantly, this pathway is dispensable for the generation of cytotoxic CD8^+^ T, Th1, and Th17 cells, highlighting its specificity in regulating the generation and function of Tfh cells.

In summary, our study identified a five-miRNA signature of Tfh cells, found that miR-22 and miR-183/96/182 are dispensable in Tfh cells, and established the miR-155--Peli1--c-Rel axis as an important pathway that regulates the generation and function of Tfh cells. In the long run, manipulating this pathway may help us to design better ways to boost immune responses to fight pathogen infections and to attenuate autoantibody production to treat autoimmune diseases.

MATERIALS AND METHODS {#s12}
=====================

Mice {#s13}
----

*miR-22^−/−^* (Jax stock 018155 on a 129S7/SvEvBrd background), *miR-155^−/−^* (Jax stock 007745 on a 129S6/SvEvTac × C57BL/6NTac mixed background), *Tcrb^−/−^Tcrd^−/−^* (Jax stock 002122 on a C57BL/6J background), OT-II (Jax stock 004194 on a C57BL/6 background), and *Rag1^−/−^* (Jax stock 002216 on a C57BL/6 background) mice were from The Jackson Laboratory. *miR-183*/*96*/*182* (on a 129 × C57BL/6 background) and *Peli1*-deficient (on a C57BL/6 background; provided by S. Sun, The University of Texas M.D. Anderson Cancer Center, Houston, TX) mice were previously described ([@bib6]; [@bib37]). *miR-155^−/−^;Peli1^+/−^* mice were generated by breeding *miR-155^−/−^* and *Peli1^−/−^* mice. All mice were bred and housed under specific pathogen-free conditions. Both male and female mice were used for all experiments, and no sex differences were observed. For BM reconstitution, BM cells isolated from C57BL/6, *miR-155^−/−^*, and *miR-155^−/−^;Peli1^+/−^* mice were subjected to red blood cell lysis and T cell depletion by magnetic cell separation, mixed with BM cells from *Tcrb^−/−^Tcrd^−/−^* mice at a 1:4 ratio (5 × 10^6^ cells in total), and transferred by tail vein injection into *Rag1^−/−^* mice irradiated with two rounds of 400 Rad with a 3-h interval ([@bib52]). 10 wk after reconstitution, recipient mice were immunized with OVA/alum/LPS i.p. For LCMV infection, mice were injected i.p. with 2 × 10^5^ PFU LCMV Armstrong and analyzed on day 8 after infection. All mice were used in accordance with guidelines from the Institutional Animal Care and Use Committees of The Scripps Research Institute and Xiamen University.

Antibodies and reagents {#s14}
-----------------------

Anti-CD4 (GK1.5), anti-CD25 (PC61), anti-CD44 (IM7), anti-CD69 (H1.2F3), anti-CD71 (RI7217), anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD40L (MR1), anti-CD90.1 (Thy1.1), anti--PD-1 (RMP1-30), anti-ICOS (15F9), and biotin anti--rat IgG2a (MRG2a-83) were from BioLegend. Anti-CXCR5 (2G8), anti--Bcl-6 (K112-91), anti-CD95 (Jo2), anti-IgD (11-26c.2a), FITC-conjugated anti-CD3 (2C11), and Alexa Fluor 647--conjugated anti-GL7 (GL7) were from BD. Anti-SHIP1 and anti-Fbxo11 were from Cell Signaling Technology. Anti-pellino1/2 (F7), c-Rel (N), p65 (C-20), and RelB (C-19) were from Santa Cruz Biotechnology, Inc. Anti--β-actin (AC-74) was from Sigma-Aldrich.

RNA isolation and miRNA expression profiling of Tfh cells {#s15}
---------------------------------------------------------

2--3-mo-old C57BL/6 mice were immunized with OVA/alum/LPS i.p. On day 7 after immunization, naive (CD4^+^CD44^−^CXCR5^−^PD1^−^), pre-Tfh (CD4^+^CXCR5^int^PD1^lo^), and Tfh (CD4^+^CXCR5^hi^PD1^hi^) cells were FACS sorted from splenocytes. Total RNA was extracted using TRIzol reagent and subjected to standard small RNA deep sequencing analysis. In brief, small RNA in the range of 18--35 nucleotides was isolated by denaturing PAGE. 5′ and 3′ adapters were added to the small RNAs sequentially, followed by RT and PCR amplification. The amplified cDNA was gel purified and loaded on the Genome Analyzer II (Illumina) for deep sequencing according to the manufacturer's instructions. The miRDeep software package was used to identify known miRNAs, predict novel miRNAs, and establish a miRNA expression profile for each sample ([@bib16]).

To identify differentially expressed miRNAs, variances and SD among samples were first calculated using the rowVars function from the gene filter library in R. Then, the miRNA expression levels of the selected most differentially regulated 60 miRNAs were subjected to heat map analysis. In the heat map, these miRNAs are ordered and clustered together when the expression patterns are similar based on row dendrogram. The small RNA deep sequencing data have been deposited on the NCBI Gene Expression Omnibus database (accession no. [GSE72975](GSE72975)).

Generation of Th cell subsets {#s16}
-----------------------------

CD62L^+^CD25^−^ naive CD4^+^ T cells in the spleen were sorted by flow cytometers (FACSAria; BD) from Foxp3-GFP (for Th0, Th1, and induced T reg \[iT reg\] cells; [@bib15]), IL-4--GFP (for Th2 cells; [@bib38]), and IL-17A--GFP mice (for Th17 cells; Jax stock 018472) and were stimulated for 4 d with 1 µg/ml anti-CD3 and mitomycin C (Sigma-Aldrich)--treated congenic allophycocyanin (APC) and 50 U/ml recombinant human IL-2 under Th0-, Th1-, iT reg--, Th2-, or Th17-polarizing conditions. Th cell polarization mediums were supplemented as follows: for Th0 cell differentiation, 10 µg/ml anti--IL-4, 10 µg/ml anti--IL-12, and 10 µg/ml anti--IFN-γ; for Th1 cell differentiation, 2 U/ml IL-12 and 10 µg/ml anti--IL-4; for Th2 cell differentiation, 20 ng/ml IL-4, 10 µg/ml anti--IL-12, and 10 µg/ml anti--IFN-γ; for iT reg cell differentiation, 1 ng/ml human TGF-β; and for Th17 cell differentiation, 2 ng/ml human TGF-β and 20 ng/ml IL-6. Th cells were sorted by the expression of CD45 congenic marker and GFP reporter. Natural T reg cells were sorted directly from Foxp3-IRES (internal ribosomal entry site)-Thy1.1 mice ([@bib32]). All antibodies were purchased from Bio X Cell, and recombinant cytokines were from PeproTech.

Flow cytometry and intracellular staining {#s17}
-----------------------------------------

Single-cell suspensions were prepared from spleen or draining lymph nodes. Antibodies for cell surface markers were added, followed by incubation for 30 min at 4°C. For staining of CXCR5, single cells were stained with purified antibody to mouse CXCR5 (2G8; BD), followed by biotin-conjugated antibody to rat IgG2a (MRG2a-83; BioLegend) and streptavidin-APC. For staining of IL-2, cell surface markers were stained, and then cells were fixed for 30 min at 4°C with 1% paraformaldehyde, permeabilized with FACS buffer (2% FBS in PBS) containing 0.1% saponin (Sigma-Aldrich), and incubated for 30 min at 4°C with APC-conjugated anti--IL-2. A Foxp3 staining kit was used to stain Bcl-6 according to the manufacturer's instructions (eBioscience). Cells on which surface markers had been stained were fixed for 1 h at 4°C with fixation/permeabilization buffer, washed with 1× permeabilization buffer, and incubated for 1 h at room temperature with anti--Bcl-6 in 1× permeabilization buffer. Apoptotic cells were assessed by using a CaspGLOWFluorescein Active Caspase-3 Staining kit according to the manufacturer's instructions (eBioscience).

Immunofluorescence microscopy {#s18}
-----------------------------

Mouse lymph nodes were washed with PBS and placed in optimal cutting temperature compound and snap frozen in dry ice. Cryosections of 6 µm in thickness were fixed with acetone and then stained with anti--mouse IgD (BioLegend), anti--rat Alexa Fluor 488 (Thermo Fisher Scientific), anti-CD45.2--APC (BioLegend), and Hoechst 33342 (Thermo Fisher Scientific). Images were acquired using a confocal microscope (780; Leica Biosystems) and analyzed with Imaris software (Bitplane).

T cell stimulation and retroviral transduction {#s19}
----------------------------------------------

Annealed oligonucleotides encoding *Peli1*-specific shRNA (5′-GATCCGGTCAACTGAAAGTCCTATTCTCGAGAATAGGACTTTCAGTTGACCGTTTTTG-3′) or mouse c-Rel cDNA from c-Rel Flag pCDNA3 (plasmid 20013; Addgene) were inserted into a Thy-1.1--expressing retroviral vector provided by A. Rao (La Jolla Institute for Allergy and Immunology, La Jolla, CA; plasmid 17442; Addgene). S-Eco packaging cells were transfected by Fu-GENE HD reagent (Promega), and retroviral supernatants were collected 48 h after transfection. Naive CD4^+^ (CD25^−^CD44^−^CD69^−^) T cells were purified as previously described ([@bib27]), stimulated with 5 µg/ml plated-bound anti-CD3 (2C11; BioLegend) and 2 µg/ml anti-CD28 (37.51; BioLegend) for 1 d, and then transduced by spin infection for 1 h at 1,800 rpm with retroviral supernatants in the presence of 6 µg/ml polybrene (Sigma-Aldrich).

Adoptive transfer of OT-II CD4^+^ T cells {#s20}
-----------------------------------------

10^6^ naive WT or *miR-155^−/−^* CD4^+^CD45.2^+^ OT-II CD4^+^ T cells were transferred into CD45.1^+^ C57BL/6 recipient mice by tail vein injection, followed by subcutaneous immunization with 25 µg OVA/alum into the flank 1 d after cell transfer. For the transfer of RV-infected WT or *miR-155^−/−^* OT-II CD4^+^ T cells, 10^6^ Thy-1.1^+^ cells were purified by magnetic cell separation and transferred into *Tcrb^−/−^Tcrd^−/−^* mice. 1 d after cell transfer, recipient mice were immunized with 25 µg OVA/alum or NP-OVA/alum i.p.

ELISA {#s21}
-----

Microtiter plates were coated with NP~30~-BSA or NP~5~-BSA (10 µg/ml in PBS; LGC Biosearch Technologies) for measurement of total or high-affinity NP-specific antibody, respectively. Nonspecific binding was blocked with 0.5% BSA in PBS. Serum samples were serially diluted in 0.5% BSA in PBS and were incubated in blocked plates at room temperature for 2 h. Plates were incubated for 2 h with biotin-conjugated anti-IgM (1020-08) or anti-IgG1 (1070-08; SouthernBiotech) for 1 h with streptavidin--alkaline phosphatase (Roche) and then with alkaline phosphatase substrate solution containing 4-nitro-phenyl phosphate (Sigma-Aldrich) for color development, followed by quantification on a microplate reader (VERSAmax; Molecular Devices).

Immunoblot analysis {#s22}
-------------------

Naive and stimulated CD4^+^ T cells were washed with PBS twice and lysed in radioimmunoprecipitation assay buffer (140 mM NaCl, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, and 0.1% SDS) supplemented with Halt Protease & Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). Cell lysates were resolved on SDS-PAGE. Primary antibodies were diluted in 5% (wt/vol) BSA or nonfat milk in 1× Tris-buffered saline buffer (10 mM Tris-HCl, pH 8.0, and 150 mM NaCl) followed by incubation overnight at 4°C.

Preparation of nuclear extracts {#s23}
-------------------------------

10 × 10^6^ naive CD4^+^ cells before or after stimulation were harvested and resuspended in 100 µl of 0.1% NP-40 lysis buffer (10 mM Tris-Cl, pH 7.5, 10 mM NaCl, 3 mM MgCl~2~, and 0.1% NP-40) and allowed to swell at 4°C for 5 min. The homogenates were centrifuged at 800 *g* for 5 min, and the supernatant was stored at −80°C as cytoplasmic extracts. The nuclear pellet was washed twice with washing buffer (10 mM Tris-Cl, pH 7.5, 10 mM NaCl, and 3 mM MgCl~2~) and resuspended in 20 µl radioimmunoprecipitation assay buffer for Western blot analysis. After incubation at 4°C for 30 min with occasional vigorous vortex mixing, the nuclear extracts were centrifuged at 16,000 *g* for 10 min at 4°C, and the supernatant was frozen in aliquots at −80°C.

Luciferase reporter assay {#s24}
-------------------------

Reporter constructs for the assay were prepared by cloning of a fragment of the Peli1 3′UTR (nucleotide position 1541--2033) containing the putative miR-155 binding site into psiCheck2 (Promega). 11 nucleotides of the miR-155 binding site spanning the miR-155 seed sequence (5′-ATTTGCATTAA-3′) were removed to generate the mutated reporter construct. The reporter constructs were cotransfected with empty or miR-155 expression plasmid into HEK293 cells. 24 h after transfection, luciferase activity was analyzed by using the Dual-Luciferase Reporter assay system (Promega) according to the manufacturer's guide.

EAE {#s25}
---

Mice were injected subcutaneously with 100 µl of an emulsion containing 100 µg MOG~35--55~ peptide (MEVGWYRSPFSRVVHLYRNGK) in complete Freund adjuvant. Mice were also injected i.p. with 200 ng pertussis toxin in 200 µl PBS on days 0 and 2 ([@bib30]).

Intracellular cytokine staining {#s26}
-------------------------------

For LCMV Armstrong--infected mice, splenocytes were harvested on day 8 after infection and stimulated for 5 h with 2 µg/ml MHC class I--restricted peptides of LCMV glycoprotein amino acids 33--41 (\>99% pure; American Peptide and The Scripps Research Institute) in the presence of 4 µg/ml brefeldin A (Sigma-Aldrich). Cells were fixed, permeabilized with 2% saponin, and stained intracellularly with anti--IFN-γ (XMG1.2; BioLegend), anti-TNF (MP6-XT22), and anti--IL-2 (JES6-5H4; BioLegend). For EAE mice, draining lymph node cells were stimulated for 5 h with 50 ng/ml PMA (eBioscience) and ionomycin (eBioscience) in the presence of brefeldin A and monensin (eBioscience). Cells were fixed and permeabilized with 2% saponin and stained with anti--IFN-γ (XMG1.2) for Th1 cell differentiation or IL-17A (TC11-18H10.1; BioLegend) for Th17 cell differentiation.

Statistics {#s27}
----------

P-values were determined by using two-tailed Student's *t* tests. Statistical significance is displayed as \*, P \< 0.05; \*\*, P \< 0.01; and \*\*\*, P \< 0.001.

Online supplemental material {#s28}
----------------------------

Table S1 contains small RNA deep sequencing analysis of Tfh cells. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20160204/DC1>.
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